Moreover, hypophysitis is more common in the treatment of another immune checkpoint blockade, cytotoxic T-lymphocyte antigen 4 antibodies (CTLA4 antibodies, such as ipilimumab), which was reported an incidence of 9.1%.[20] Routine monitoring is also necessary in those patients. Here, CTLA4 is linked to hypophysitis.